Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMG1 | Q96Q15 | 4/20 | 0.59 |
| ▸ | MTOR | P42345 | 3/20 | 0.59 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | CDK1 | P06493 | 4/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
| ▸ | CLK3 | P49761 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633026 | 0.93 | SMG1 (0.59) | SMG1MTORMAP4K1AURKACDK2 | |
| SCHEMBL1631045 | 0.84 | SMG1 (0.59) | SMG1MTORMAP4K1CDK2CDK1 | |
| SCHEMBL1632085 | 0.84 | SMG1 (0.62) | SMG1MTORAURKACDK2CDK1 | |
| SCHEMBL1631324 | 0.83 | MAP4K1 (0.59) | SMG1MTORMAP4K1AURKACDK2 | |
| SCHEMBL1633017 | 0.82 | SMG1 (0.72) | SMG1MTORMAP4K1CDK2CDK1 | |
| SCHEMBL1869104 | 0.80 | CDK2 (0.66) | BRAFMAP4K1CDK2CDK1CCNE1 | |
| SCHEMBL1869926 | 0.77 | MTOR (0.52) | SMG1MTORCDK2CDK1JAK2 | |
| SCHEMBL1632364 | 0.75 | FGFR4 (0.48) | SMG1MTORAURKACDK2CDK1 | |
| SCHEMBL1571348 | 0.75 | IKBKB (0.49) | BRAFAURKACDK2CDK1CCNT1 | |
| SCHEMBL1633192 | 0.74 | JAK2 (0.55) | SMG1MTORAURKACDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SMG1 949/4885MTOR 86/4885STK17A 103/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | SMG1 1358/4885MTOR 24/4885STK17A 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.